Ocular Therapeutix Inc. (NASDAQ:OCUL) is a low-priced stock with high upside potential. Bank of America raised the price target to $21 from $18, maintaining a Buy rating. The firm is optimistic about AXPAXLI’s unique advantages, faster regulatory path, and pivotal trials in wet AMD and diabetic retinopathy.

Ocular Therapeutix Inc. (NASDAQ:OCUL) accelerates its regulatory strategy for AXPAXLI, planning to submit an NDA after one-year data from its SOL-1 Phase 3 trial. Topline results are expected in Q1 2026. The FDA suggests a single, well-powered trial may suffice for approval, aligning with SOL-1’s design under a Special Protocol Assessment agreement.

Ocular Therapeutix Inc. (NASDAQ:OCUL) believes SOL-1 meets FDA standards for approval, comparing AXPAXLI to aflibercept in a superiority trial. The study completed randomization in December 2024 with 344 subjects, assessing visual acuity maintenance at week 36 as the primary endpoint. BofA remains optimistic about the drug’s prospects.

Ocular Therapeutix Inc. (NASDAQ:OCUL) develops therapies for retinal diseases and eye conditions using bioresorbable hydrogel-based formulations. The company focuses on advancing AXPAXLI for wet AMD treatment. BofA highlights the drug’s potential for a faster regulatory path and competitive advantages.

While Ocular Therapeutix Inc. (NASDAQ:OCUL) shows promise, some AI stocks offer greater upside potential with lower downside risk. Investors seeking undervalued AI stocks can explore opportunities outside the eye care sector. Consider exploring AI stocks poised to benefit from current market trends for potential investment opportunities.

Read more at Yahoo Finance: BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD